Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, All-Comers Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor Malignancies

NCT06175221 is registered in ClinicalTrials.gov with Elios Therapeutics, LLC as lead sponsor.

NCT NCT06175221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06175221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, All-Comers Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor Malignancies
Lead sponsor
Elios Therapeutics, LLC
Phase
Phase 2
Overall status
Terminated
Start date
November 29, 2023
Completion date
July 2, 2025
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, tumor, tumor metastasis, tumor, solid